ECM
IMDX

Element Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Element Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,284
Closed -$114K – 816
2018
Q3 		$114K Sell
2,284
-642
-22% -$33.1K ﹤0.01% 838
2018
Q2 		$149K Buy
+2,926
New +$144K ﹤0.01% 773

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WJA
Williams Jones & Associates New York $4.82B AUM 19.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Element Capital Management's IMDX Position: Q4 2018 in Review

Element Capital Management sold out of Insight Molecular Diagnostics (IMDX) in Q4 2018, closing a stake of 2,284 shares — an estimated $114K sold.

Element Capital Management first reported a position in IMDX in Q2 2018 and held it in 2 quarters. The position peaked at $149K in Q2 2018. 22 funds tracked by Wall St. Rank hold IMDX as of Q4 2018.

  • Element Capital Management reported no remaining Insight Molecular Diagnostics position as of Q4 2018 after selling out during the quarter.
  • Element Capital Management sold 2,284 Insight Molecular Diagnostics shares in Q4 2018, an estimated $114K.
  • Element Capital Management first reported a position in Insight Molecular Diagnostics in Q2 2018 and held it in 2 quarters.
  • Element Capital Management's Insight Molecular Diagnostics position peaked at $149K in Q2 2018.
  • 22 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.